Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: a secondary analysis of an open-label, randomised, controlled, phase 2 trial

医学 曲美替尼 吉西他滨 临床终点 肿瘤科 内科学 彭布罗利珠单抗 胰腺癌 放射治疗 临床试验 癌症 免疫疗法 MAPK/ERK通路 生物 细胞生物学 激酶
作者
Xiaofei Zhu,Wenyu Liu,Yangsen Cao,Xingzhu Ju,Xianzhi Zhao,Lingong Jiang,Yusheng Ye,Huojun Zhang
出处
期刊:EClinicalMedicine [Elsevier BV]
卷期号:55: 101764-101764 被引量:2
标识
DOI:10.1016/j.eclinm.2022.101764
摘要

There are a lack of studies about whether radiation dose escalation synergizes with immunotherapy and targeted therapy in pancreatic cancer. In this study, we performed a secondary analysis to investigate whether a high radiation dose rather than a low dose plus pembrolizumab and trametinib provided improved survival compared with gemcitabine in post-operative locally recurrent pancreatic cancer.In this open-label, randomised, controlled, phase 2 trial, eligible patients with pancreatic ductal adenocarcinoma characterized by mutant KRAS and positive immunohistochemical staining of PD-L1 and documented post-operative local recurrence were randomly assigned using an interactive voice or web response system, without stratification, to receive stereotactic body radiation therapy (SBRT) with doses ranging from 35 to 40Gy in five fractions, pembrolizumab 200 mg every three weeks and oral trametinib 2 mg once daily (SBRT + K + M) or SBRT and gemcitabine (1000 mg/m2) on day 1 and 8 of each 21-day cycle (SBRT + G) until disease progression in our hospital in China. Those had radiotherapy, immunotherapy or targeted therapy were excluded. Patients and investigators were not masked to the assignment. In each arm, patients were stratified based on biologically effective dose (BED10; α/β = 10) of 60-65Gy and BED10 ≥65Gy. The primary endpoint was overall survival (OS) and the secondary endpoint was progression-free survival (PFS). All patients received their assigned treatment and were included in the efficacy and safety analyses. This study is registered with ClinicalTrials.gov, NCT02704156.Between Oct 10, 2016, and Oct 28, 2017, 147 of 170 randomly assigned participants were eligible for inclusion in this analysis. In BED10 of 60-65Gy group, 34 and 29 patients had SBRT + G and SBRT + K + M, respectively. While there were 42 and 42 patients with SBRT + G and SBRT + K + M in BED10 ≥65Gy group. Patients in the SBRT + K + M group had longer OS compared with the SBRT + G group, but this did not reach statistical significance (median: 15.1 vs. 12.4 months, HR 0.67 [95%CI 0.43-1.04]; p = 0.071). For BED10 of 60-65Gy, OS was similar between patients in the SBRT + K + M and SBRT + G groups (median, 13.6 vs. 12.4 months; HR 0.69 [95% CI 0.41-1.16]; p = 0.16). For BED10 of ≥65Gy, PFS was prolonged with SBRT + K + M versus SBRT + G (median: 8.6 vs. 5.0 months, HR 0.48 [95% CI 0.31-0.77]; p = 0.0021). For BED10 of 60-65Gy, there was no significant difference in PFS between the two groups (PFS: median, 7.9 vs. 4.3 months; HR 0.69 [95% CI 0.42-1.15]; p = 0.16). In BED10 of 60-65Gy group, 7 (20.6%) and 8 patients (27.6%) with SBRT + G and SBRT + K + M had grade 3 or 4 adverse events (p = 0.52). In BED10 ≥65Gy group, 8 (19.0%) and 12 patients (28.6%) with SBRT + G and SBRT + K + M had grade 3 or 4 adverse events (p = 0.31). No treatment-related death occurred.Dose escalation of SBRT may improve PFS with pembrolizumab and trametnib versus gemcitabine for patients with post-operative locally recurrent pancreatic cancer. However, benefits of PFS did not translate into longer OS. This may be ascribed to small sample size and post-hoc analysis that was not powered to determine the significance. Therefore, synergy of high dose of SBRT with immunotherapy and targeted therapy required further investigations in phase 3 trials.Shanghai Shenkang Centre and Changhai Hospital.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
nn发布了新的文献求助10
1秒前
求助完成签到,获得积分10
2秒前
3秒前
翁雁丝完成签到 ,获得积分10
10秒前
郭义敏完成签到,获得积分0
10秒前
gyf完成签到,获得积分10
13秒前
李保龙完成签到 ,获得积分10
14秒前
18秒前
LJJ完成签到 ,获得积分10
19秒前
量子星尘发布了新的文献求助10
22秒前
阿姨洗铁路完成签到 ,获得积分10
27秒前
抹不掉的记忆完成签到,获得积分10
29秒前
29秒前
余杭村王小虎完成签到,获得积分10
30秒前
韭黄完成签到,获得积分20
34秒前
jeffrey完成签到,获得积分10
34秒前
Rondab应助机灵枕头采纳,获得10
40秒前
佳无夜完成签到,获得积分10
45秒前
摆哥完成签到,获得积分10
49秒前
66完成签到,获得积分10
54秒前
zlqq完成签到 ,获得积分10
54秒前
Hardskills发布了新的文献求助10
57秒前
58秒前
之_ZH完成签到 ,获得积分10
1分钟前
gds2021完成签到 ,获得积分10
1分钟前
你好呀嘻嘻完成签到 ,获得积分10
1分钟前
梅特卡夫完成签到,获得积分10
1分钟前
熊雅完成签到,获得积分10
1分钟前
1分钟前
睡到自然醒完成签到 ,获得积分10
1分钟前
cis2014完成签到,获得积分10
1分钟前
独特的大有完成签到 ,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
1分钟前
xingyi完成签到,获得积分10
1分钟前
1分钟前
舒心的秋荷完成签到 ,获得积分10
1分钟前
zz123发布了新的文献求助10
1分钟前
liaomr完成签到 ,获得积分10
1分钟前
粗犷的灵松完成签到,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038112
求助须知:如何正确求助?哪些是违规求助? 3575788
关于积分的说明 11373801
捐赠科研通 3305604
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022